Avigen Inc.
1301 Harbor Bay Parkway
Alameda,
CA 94502
United States - Map
Phone: 510-748-7150
Fax: 510-748-7155
Web Site: http://www.avigen.com
| Avigen, Inc., a development stage biopharmaceutical company, focuses on identifying and developing products to treat patients with neurological and other disorders. The company develops the AV411 portfolio, which includes the phase II-stage lead drug compound and proprietary analogs and represents novel, non-opioid drugs for the treatment of various large pain and drug addiction indications. AV411 is an orally bioavailable small molecule; a glial attenuator that suppresses pro-inflammatory cytokines IL-1 beta, TNF alpha, and IL-6; and a toll-like receptor 4 (TLR4) functional antagonist that may contribute to its attenuation of neuroinflammation. AV411 is being evaluated in Phase Ib/IIa clinical trials. The company was founded in 1992 and is headquartered in Alameda, California. |
|
| Key Statistics |
| |
| | Pay | Exercised | Mr. Andrew A. Sauter , 42
Chief Exec. Officer and Pres |
$
310.00K |
$
27.00K | Dr. John K. A. Prendergast Ph.D., 55
Co-Founder, Lead Independent Director, Chairman of Audit Committee, Chairman of Corp. Governance & Nominating Committee and Chairman of Compensation Committee
|
$
42.00K | N/A | Dr. Kirk W. Johnson Ph.D., 49
VP of R&D and Sec. |
N/A
| N/A | Dr. Michael Hensley M.D.,
Head of Regulatory Affairs |
N/A
| N/A | Dr. Drew Jones M.D., M.P.H.,
Sr. Director of Clinical Affairs |
N/A
| N/A |
|
|
|
Dollar amounts are as of
31-Dec-08
and compensation values are for the last fiscal
year ending on that date. "Pay" is salary, bonuses, etc. "Exercised" is the value of
options exercised during the fiscal year.
| |
|
0.06% Nasdaq 0.00%
Profile
